PubMed · 2643854
Evidence for the interaction of urapidil with 5-HT1A receptors in the brain leading to a decrease in blood pressure.
Abstract
Current knowledge about the role of serotonin (5-HT) in central cardiovascular regulation is reviewed. Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column. As a consequence, blood pressure is reduced by 5-HT1A receptor agonists. Urapidil is an antihypertensive drug that has a dual mode of action: peripheral alpha-adrenoceptor antagonism and interaction with 5-HT1A receptors in the brain. This profile can adequately explain the vasodilation and lack of significant sympathetic activation observed during urapidil treatment.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
N Kolassa, K D Beller, K H Sanders. 1989-02-02. Evidence for the interaction of urapidil with 5-HT1A receptors in the brain leading to a decrease in blood pressure.. https://doi.org/10.1016/0002-9149(89)90404-9
Cite the original work for its findings. Save a collection to share your selection of sources.